Moderna's Trading Volume Drops 57% Despite FDA Approval of New COVID-19 Vaccine mNEXSPIKE

On June 2, 2025, Moderna's trading volume reached $348 million, marking a 57.16% decrease from the previous day. The company's stock price rose by 1.84%.

Moderna's latest COVID-19 vaccine, mNEXSPIKE (mRNA-1283), has received approval from the FDA. This new vaccine is designed to protect against COVID-19 and is approved for use in adults aged 65 and older, as well as individuals aged 12 to 64 who have at least one underlying condition that puts them at high risk for severe infection.

The approval of mNEXSPIKE is based on Phase III trial data, which demonstrated a 9.3% higher relative vaccine efficacy compared to Moderna's original COVID-19 vaccine, Spikevax. The trial enrolled approximately 11,400 participants aged 12 and older, and the vaccine showed fewer local reactions compared to Spikevax, with comparable side effects such as injection site pain, fatigue, headache, and myalgia.

Moderna expects mNEXSPIKE to be available for the 2025-2026 respiratory virus season in the US and is currently under review in other nations. The company also stated that Spikevax will continue to be available in the US.